SCHEMBL5263242

SCHEMBL5263242

COc1ccc2nccc(NC(=O)C3(O)CCCCC3NC(=O)OC(C)(C)C)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.42
SLC22A12 Q96S37 1/20 0.40
HTR1A P08908 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
LMNA P02545 1/20 0.39
KDR P35968 4/20 0.38
RIPK2 O43353 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPK1 P28482 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
EGFR P00533 2/20 0.37
GAK O14976 1/20 0.37
COQ8A Q8NI60 1/20 0.37
NLK Q9UBE8 1/20 0.37
RET P07949 1/20 0.37
PDGFRB P09619 1/20 0.37
KIT P10721 1/20 0.37
FGFR1 P11362 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5635423 0.86 ALDH1A1 (0.35) KDRMAPK1EGFRRETPDGFRB
SCHEMBL3583797 0.85 JAK1 (0.35) SLC22A12KDREGFRRETPDGFRB
SCHEMBL5260906 0.79 CDK8 (0.41) KDRGSK3AGSK3B
SCHEMBL5266247 0.78 KCNH2 (0.58) KCNH2HTR1AADRA1DADRA1AADRA1B
SCHEMBL5264535 0.77 KCNH2 (0.37) KCNH2NPSR1RETALDH1A1
Ammonia Solution, Strong SCHEMBL6643042 0.77 KCNH2 (0.57) KCNH2HTR1AADRA1DADRA1AADRA1B
SCHEMBL4268442 0.76 ATM (0.48) KCNH2ALDH1A1MTNR1BPIK3CAMTOR
SCHEMBL3580109 0.76 TYK2 (0.33) KDM4ERETALDH1A1
SCHEMBL3581356 0.72 ADAM17 (0.34) KCNH2
SCHEMBL3581635 0.72 ADAM17 (0.36) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399443-B1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2007-12-12 EP disclosed
US-7141564-B2 Nitrogen-containing bicyclic heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2006-11-28 US disclosed
US-20040171620-A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-09-02 US disclosed
EP-1399443-A1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-03-24 EP disclosed
WO-2003087098-A1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171620-A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials NRDC, NUCB2, NDC1 KCNH2 3311/4885SLC22A12 1520/4885HTR1A 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.